Xiao Li

5PUBLICATIONS
7CO-AUTHORS
Respiratory diseasesPredictive and prognostic markersHaematological tumoursMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 29, 2023
ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS.

Jia-Cheng Jin, Bing-Yi Chen, Chu-Han Deng

|Aug 31, 2021
Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.

Xiao Li, Feng Xu, Zheng Zhang

|Jun 29, 2021
U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.

Yuqian Zhu, Dandan Song, Juan Guo

|Apr 09, 2020
NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy.

Lingyun Wu, Xiao Li, Feng Xu

|Sep 28, 2019
The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.

Cai Xiu, Xiao Li, Lingyun Wu

Pageof 1

Frequent Collaborators

1 joint publications

Jia-Cheng Jin

1 joint publications

Bing-Yi Chen

1 joint publications

Cheng-Long Hu

1 joint publications

Chun-Hui Xu